Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
112.46 +1.06 (+0.95%) 17:45 ET [NYSE]
111.98 x 100 116.00 x 100
Realtime by (Cboe BZX)
111.98 x 100 116.00 x 100
Realtime 112.57 unch (unch) 17:19 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
111.26
Day High
112.85
Open 111.64
Previous Close 111.40 111.40
Volume 2,538,021 2,538,021
Avg Vol 2,536,866 2,536,866
Stochastic %K 49.43% 49.43%
Weighted Alpha +15.91 +15.91
5-Day Change +0.44 (+0.39%) +0.44 (+0.39%)
52-Week Range 92.35 - 120.92 92.35 - 120.92
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 227,701,600
  • Shares Outstanding, K 2,044,000
  • Annual Sales, $ 51,722 M
  • Annual Income, $ 11,941 M
  • EBIT $ 14,544 M
  • EBITDA $ 20,658 M
  • 60-Month Beta 0.53
  • Price/Sales 4.47
  • Price/Cash Flow 10.29
  • Price/Book 5.10

Options Overview Details

View History
  • Implied Volatility 19.73% ( -1.18%)
  • Historical Volatility 21.64%
  • IV Percentile 54%
  • IV Rank 56.58%
  • IV High 25.21% on 04/19/24
  • IV Low 12.60% on 05/16/24
  • Put/Call Vol Ratio 0.45
  • Today's Volume 833
  • Volume Avg (30-Day) 5,542
  • Put/Call OI Ratio 1.01
  • Today's Open Interest 55,759
  • Open Int (30-Day) 59,332

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.07
  • Number of Estimates 4
  • High Estimate 2.24
  • Low Estimate 1.96
  • Prior Year 1.80
  • Growth Rate Est. (year over year) +15.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
107.64 +4.58%
on 03/14/25
Period Open: 109.05
116.91 -3.71%
on 03/10/25
+3.52 (+3.23%)
since 02/28/25
3-Month
96.91 +16.16%
on 01/02/25
Period Open: 98.39
116.91 -3.71%
on 03/10/25
+14.18 (+14.41%)
since 12/27/24
52-Week
92.35 +21.89%
on 04/18/24
Period Open: 96.73
120.92 -6.91%
on 08/30/24
+15.84 (+16.38%)
since 03/28/24

Most Recent Stories

More News
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END

AZN : 73.79 (+1.30%)
LLY : 822.51 (+0.10%)
NVS : 112.57 (+1.05%)
ATNM : 1.8100 (-4.23%)
BMY : 60.02 (+1.90%)
5 Large Drug Stocks to Watch as Industry Recovers

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due to the better-than-expected fourth-quarter performance of large drugmakers and...

BAYRY : 6.1435 (+0.06%)
NVO : 69.30 (-1.23%)
NVS : 112.57 (+1.05%)
ABBV : 205.29 (+1.27%)
PFE : 25.21 (+0.80%)
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains

The medical sector is one of the major adopters of artificial intelligence (AI), which is currently being used to synthesize new compounds for drugs and create devices for more precise measurement and...

ABT : 130.82 (-0.40%)
BSX : 99.36 (-1.43%)
LLY : 822.51 (+0.10%)
NVS : 112.57 (+1.05%)
MDT : 87.63 (-0.74%)
FDA Approves Novartis Drug for Rare Kidney Disease Treatment

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication.The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria.C3G...

BAYRY : 6.1435 (+0.06%)
NVS : 112.57 (+1.05%)
GILD : 111.79 (+0.57%)
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3...

AZN : 73.79 (+1.30%)
JNJ : 163.71 (+0.36%)
NVS : 112.57 (+1.05%)
PFE : 25.21 (+0.80%)
SNY : 55.82 (+1.66%)
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201.DR-0201 is...

NVS : 112.57 (+1.05%)
REGN : 637.36 (+0.24%)
PFE : 25.21 (+0.80%)
SNY : 55.82 (+1.66%)
The Best Vanguard ETF to Invest $1,000 in Right Now

What to invest in now -- that may seem like a tough decision, given the current economic uncertainty in the U.S. including ongoing tariff-related concerns. Investors are worried about inflation, about...

SONY : 25.09 (-2.15%)
SAP : 268.00 (-0.06%)
SPGI : 502.51 (-1.21%)
NVS : 112.57 (+1.05%)
RHHBY : 41.9200 (-1.02%)
VIGI : 83.25 (-0.91%)
NSRGY : 102.3400 (+0.52%)
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic...

ALNY : 268.46 (-0.94%)
NVS : 112.57 (+1.05%)
REGN : 637.36 (+0.24%)
RHHBY : 41.9200 (-1.02%)
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy?

After more than two years of a bull market run, the broader benchmark S&P 500 (SNPINDEX: ^GSPC) is starting to show some cracks. The index has given up all its post-election gains and finished Monday's...

SONY : 25.09 (-2.15%)
NVO : 69.30 (-1.23%)
$SPX : 5,580.94 (-1.97%)
RY : 112.14 (-2.24%)
NVS : 112.57 (+1.05%)
HSBC : 57.77 (-0.98%)
MUFG : 13.98 (-3.19%)
NSRGY : 102.3400 (+0.52%)
HTHIY : 23.9600 (-2.88%)
CBA.AX : 150.430 (+0.26%)
VYMI : 74.00 (-0.92%)
SHEL : 72.73 (-0.76%)
Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™

/CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) welcomes the Government of Alberta's decision to publicly reimburse Pluvicto™ (lutetium (177Lu)...

NVS : 112.57 (+1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy,...

See More

Key Turning Points

3rd Resistance Point 114.78
2nd Resistance Point 113.81
1st Resistance Point 113.19
Last Price 112.57
1st Support Level 111.61
2nd Support Level 110.64
3rd Support Level 110.02

See More

52-Week High 120.92
Last Price 112.57
Fibonacci 61.8% 110.01
Fibonacci 50% 106.63
Fibonacci 38.2% 103.26
52-Week Low 92.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies